<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PEGINTERFERON ALFA-2B</span><br/>(peg-in-ter-fer'on)<br/><span class="topboxtradename">PEG-Intron<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span>; <span class="classification">interferon</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mcg/mL, 160 mcg/mL, 240 mcg/mL, 300 mcg/mL powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Binds to specific membrane receptors on the cell surface thereby initiating enzyme induction, suppression of cell proliferation,
         enhanced phagocytic activity of macrophages, augmentation of specific cytotoxic lymphocytes for target cells, and inhibition
         of viral replication in virus-infected cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces antiviral effects by activation of macrophages, natural killer cells, and T-cells, thus boosting cellular immunity
         and suppressing hepatic inflammation and replication of hepatitis C virus.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Chronic hepatitis C.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Renal carcinoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to peginterferon; autoimmune hepatitis; decompensated liver disease; persistently severe or worsening S&amp;S
         of life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of neuropsychiatric disorder; bone marrow suppression; ulcerative and hemorrhagic colitis; pancreatitis; pulmonary
         disorders; HBV or HIV coinfection; thyroid dysfunction; diabetes mellitus; cardiovascular disease; autoimmune disorders; retinal
         disease; renal impairment with creatinine clearance 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Hepatitis C</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> Based on weight and injected once weekly times 1 y: <i>3745 kg</i>, 40 mcg; <i>4656 kg,</i> 50 mcg; <i>5772 kg,</i> 64 mcg; <i>7388 kg,</i> 80 mcg; <i>89106 kg,</i> 96 mcg; <i>107136 kg</i>, 120 mcg; <i>137160 kg,</i> 150 mcg.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Give dose on the same day of each week.</li>
<li>Be aware that two Safety Lok<sup>TM</sup> syringes are provided in the drug package: one for reconstitution and one for injection. Reconstitute with only 0.7 mL of
            supplied diluent and discard remaining diluent. Enter the vial only once as it does not contain a preservative. Swirl gently
            to produce a clear, colorless solution. Use solution immediately.
         </li>
<li>Serious adverse reactions warrant reduction or discontinuation of dose.</li>
<li>Store dry vial at 15°30° C (59°86° F). If necessary, store reconstituted solution up to 24
            h at 2°8° C (36°46° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Musculoskeletal pain, fatigue, inflammation at injection site, flu-like symptoms, rigors, fever, weight loss, viral infection,</span> pain, malaise, hypertonia. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, depression, anxiety, emotional lability, irritability, insomnia, dizziness.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Nausea, anorexia, diarrhea, abdominal pain,</span> vomiting, dyspepsia, hepatomegaly. <span class="typehead">Endocrine:</span> Hypothyroidism. <span class="typehead">Hematologic:</span> Thrombocytopenia, neutropenia. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Pharyngitis,</span> sinusitis, cough. <span class="typehead">Skin:</span>
<span class="speceff-common">Alopecia, pruritus, dry skin,</span> sweating, rash, flushing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>theophylline</b> levels; additive myelosuppression with <span class="classification">antineoplastics</span>; <b>zidovudine</b> may increase hematologic toxicity; increase <b>doxorubicin</b> toxicity, increase neurotoxicity with <b>vinblastine;</b>
<b>aldesleukin (IL-2)</b> may potentiate the risk of kidney failure. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1544 h. <span class="typehead">Duration:</span> 4872 h. <span class="typehead">Elimination:</span> 30% excreted in urine. <span class="typehead">Half-Life:</span> 40 h (2260 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity (e.g., angioedema, bronchoconstriction) and, if noted, institute appropriate medical action
            immediately. Note that transient rashes are not an indication to discontinue treatment.
         </li>
<li>Monitor for and report immediately S&amp;S of neuropsychiatric disorders (e.g., psychosis, hallucinations, suicidal ideation,
            depression).
         </li>
<li>Monitor respiratory and cardiovascular status; report dyspnea, chest pain, and hypotension immediately; baseline and periodic
            ECG and chest X-ray.
         </li>
<li>Lab tests: Baseline and periodic creatinine clearance, CBC with differential, platelet count, Hct &amp; Hgb, TSH, ALT, AST, bilirubin,
            blood glucose; with diabetics or hypertensives. Serum HCV RNA levels are assessed after 24 wk of treatment.
         </li>
<li>Withhold drug and notify physician for any of the following: severe neuropsychiatric events, severe neutropenia or thrombocytopenia,
            abdominal pain accompanied by bloody diarrhea and fever, S&amp;S of pancreatitis, or any other severe adverse event (see <small>CAUTIOUS USE</small>).
         </li>
<li>Baseline and periodic ophthalmology exams are recommended.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drink fluids liberally while taking this drug, especially during the initial stages of therapy.</li>
<li>Learn reasons for withholding drug (see <small>ASSESSMENT</small> &amp; <small>DRUG EFFECTS</small>).
         </li>
<li>Use effective means of contraception while taking this drug. Women should not become pregnant.</li>
<li>Follow up with lab tests; compliance with lab testing is extremely important while taking this drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>